Fecal Calprotectin Test Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report 2026-2030

Fecal calprotectin testing has become a standard tool in gastroenterology for differentiating between organic and functional gastrointestinal disorders by measuring neutrophil-derived calprotectin in stool. The global market in 2025 sits at approximately $5.54 billion in estimated value, with most projections pointing toward roughly $9.6 billion by the end of the decade. Multiple industry analyses consistently estimate compound annual growth rates around 11% through 2030, reflecting strong and sustained demand for this diagnostic category.

• •Market valued at approximately $5.54 billion in 2025
• •Projected to reach nearly $9.6 billion by 2030
• •Estimated CAGR of approximately 11% through 2030

The increasing global incidence of inflammatory bowel diseases is a primary catalyst, as fecal calprotectin testing plays a central role in diagnosis, disease monitoring, and treatment response assessment. The test's advantage as a non-invasive, cost-effective alternative to endoscopic procedures has expanded adoption in both specialist gastroenterology clinics and primary care settings. Growing awareness among physicians about the clinical utility of fecal calprotectin in distinguishing irritable bowel syndrome from organic bowel inflammation continues to drive utilization rates.

• •Rising prevalence of Crohn's disease and ulcerative colitis globally
• •Non-invasive nature reduces reliance on endoscopic procedures
• •Cost-effectiveness compared to imaging-based diagnostic approaches

The market is typically divided by test type, including laboratory-based enzyme immunoassays and point-of-care rapid tests, as well as by end-use setting such as hospitals, diagnostic laboratories, and ambulatory care centers. North America represents the largest regional market, supported by high disease prevalence, established healthcare infrastructure, and strong adoption of diagnostic innovation, with the U.S. segment alone estimated at over $2 billion in recent assessments. Europe and the Asia-Pacific region follow, with the latter showing accelerated growth due to improving healthcare access and rising awareness of inflammatory bowel disease management.

• •North America leads in market share with U.S. estimated above $2 billion
• •Test types include laboratory immunoassays and point-of-care rapid tests
• •Asia-Pacific emerging as a fastest-growing regional market

What are the recent trends and outlook?

The shift toward decentralized testing and point-of-care diagnostics is influencing product development, with manufacturers investing in rapid lateral flow assays and automated immunoassay platforms suitable for routine clinical laboratories. Artificial intelligence integration for result interpretation and the development of multiplex panels that combine calprotectin with other inflammatory markers represent emerging innovation areas. The market is expected to maintain its robust growth trajectory through 2030 as healthcare systems prioritize early detection and personalized medicine approaches for inflammatory bowel disease management.

• •Point-of-care and rapid testing formats gaining prominence
• •AI-assisted result interpretation and multiplex panel development emerging
• •Strong growth trajectory expected through 2030